Nitric oxide inhalation - Mallinckrodt

Drug Profile

Nitric oxide inhalation - Mallinckrodt

Alternative Names: Ik 7001; IK-3001; IK-7001; INOflo; INOmax; INOmax Total Care; INOMAX® Total Care package; INOtherapy; INOVENT

Latest Information Update: 26 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Massachusetts General Hospital
  • Developer AGA Linde Healthcare; Ikaria Holdings; Mallinckrodt plc
  • Class Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antifungals; Antihypertensives; Antivirals; Free radicals; Macromolecular substances; Nitrogen oxides; Non-opioid analgesics; Small molecules; Vasodilators
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension; Hypoxic respiratory failure
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypoxic respiratory failure
  • Registered Pulmonary hypertension
  • Phase III Bronchopulmonary dysplasia
  • Discontinued Heart failure; Reperfusion injury

Most Recent Events

  • 23 Sep 2016 Mallinckrodt has patent protection for nitric oxide inhalation and gas delivery systems in USA
  • 23 Sep 2016 Praxair files an appeal against the Patent Trial and Appeal Board decision related to the US patent no. 8 846 112 in U.S. Court of Appeals for the Federal Circuit and Mallinckrodt also files a cross-appeal
  • 23 Sep 2016 The US Patent and Trademark Office confirms the validity of five 2031 patents protecting nitric oxide inhalation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top